Trevor D Hadley1, Ali M Agha1, Christie M Ballantyne2. 1. Department of Medicine and Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, One Baylor Plaza, MS BCM285, Houston, TX, USA. 2. Department of Medicine and Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, One Baylor Plaza, MS BCM285, Houston, TX, USA. cmb@bcm.edu.
Abstract
PURPOSE OF REVIEW: The potential of polygenic risk scores (PRS) to improve atherosclerotic cardiovascular disease (ASCVD) risk assessment and management has stoked significant interest in their incorporation into clinical management. The goal of this review is to apprise the readers of the latest developments and evidence of PRS readiness for clinical integration. We also discuss current limitations that must be addressed before PRS can be implemented into routine clinical practice. RECENT FINDINGS: PRS have been shown to improve risk stratification for ASCVD and to identify patients who may derive increased benefit from primary and secondary prevention. Risk captured by PRS appears largely independent of traditional risk factors and can be ascertained at birth, prior to the development of traditional clinical risk factors. Genetic risk is modifiable through lifestyle modifications and medications. PRS offers a valuable way to improve early identification of actionable CVD risk. However, further work is needed before PRS can be implemented clinically.
PURPOSE OF REVIEW: The potential of polygenic risk scores (PRS) to improve atherosclerotic cardiovascular disease (ASCVD) risk assessment and management has stoked significant interest in their incorporation into clinical management. The goal of this review is to apprise the readers of the latest developments and evidence of PRS readiness for clinical integration. We also discuss current limitations that must be addressed before PRS can be implemented into routine clinical practice. RECENT FINDINGS: PRS have been shown to improve risk stratification for ASCVD and to identify patients who may derive increased benefit from primary and secondary prevention. Risk captured by PRS appears largely independent of traditional risk factors and can be ascertained at birth, prior to the development of traditional clinical risk factors. Genetic risk is modifiable through lifestyle modifications and medications. PRS offers a valuable way to improve early identification of actionable CVD risk. However, further work is needed before PRS can be implemented clinically.
Authors: Iftikhar J Kullo; Hayan Jouni; Erin E Austin; Sherry-Ann Brown; Teresa M Kruisselbrink; Iyad N Isseh; Raad A Haddad; Tariq S Marroush; Khader Shameer; Janet E Olson; Ulrich Broeckel; Robert C Green; Daniel J Schaid; Victor M Montori; Kent R Bailey Journal: Circulation Date: 2016-02-25 Impact factor: 29.690
Authors: Wiley V Chan; Thomas A Pearson; Glen C Bennett; William C Cushman; Thomas A Gaziano; Paul N Gorman; Joel Handler; Harlan M Krumholz; Robert F Kushner; Thomas D MacKenzie; Ralph L Sacco; Sidney C Smith; Victor J Stevens; Barbara L Wells; Graciela Castillo; Susan K R Heil; Jennifer Stephens; Julie C Jacobson Vann Journal: Circulation Date: 2017-01-26 Impact factor: 29.690
Authors: Amit V Khera; Mark Chaffin; Seyedeh M Zekavat; Ryan L Collins; Carolina Roselli; Pradeep Natarajan; Judith H Lichtman; Gail D'Onofrio; Jennifer Mattera; Rachel Dreyer; John A Spertus; Kent D Taylor; Bruce M Psaty; Stephen S Rich; Wendy Post; Namrata Gupta; Stacey Gabriel; Eric Lander; Yii-Der Ida Chen; Michael E Talkowski; Jerome I Rotter; Harlan M Krumholz; Sekar Kathiresan Journal: Circulation Date: 2019-03-26 Impact factor: 29.690
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: Circulation Date: 2018-11-10 Impact factor: 29.690
Authors: Donald M Lloyd-Jones; Byung-Ho Nam; Ralph B D'Agostino; Daniel Levy; Joanne M Murabito; Thomas J Wang; Peter W F Wilson; Christopher J O'Donnell Journal: JAMA Date: 2004-05-12 Impact factor: 56.272
Authors: Gad Abraham; Aki S Havulinna; Oneil G Bhalala; Sean G Byars; Alysha M De Livera; Laxman Yetukuri; Emmi Tikkanen; Markus Perola; Heribert Schunkert; Eric J Sijbrands; Aarno Palotie; Nilesh J Samani; Veikko Salomaa; Samuli Ripatti; Michael Inouye Journal: Eur Heart J Date: 2016-09-21 Impact factor: 29.983